- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05232006
PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers (PALB2-PARPi-01)
21. februar 2022 opdateret af: Assistance Publique - Hôpitaux de Paris
Phase II Clinical Trial Aiming at Investigating the Effect of a PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers
The study aims at exploring the potential benefit of a PARP-inhibitor, Niraparib, in metastatic breast cancer developing in germline-PALB2 mutations carriers.
This study is designed as a multicentre one-arm two-stage phase 2 clinical trial
Studieoversigt
Status
Ikke rekrutterer endnu
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
12
Fase
- Fase 2
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Odile Cohen Haguenauer, MD PhD
- Telefonnummer: + 33 1 42 49 47 98
- E-mail: odile.cohen-haguenauer@aphp.fr
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Adult patients over 18 years
- PALB2 germline heterozygous mutation carrier, wild type BRCA1&2 (breast cancer 1&2) affected with metastatic breast cancer in first metastatic treatment line or beyond
- Histologically or cytologically confirmed breast cancer with evidence of metastatic disease.
- Triple Negative breast cancer; Patients affected with triple negative cancers should have received anthracyclines and taxanes in neo/adjuvant therapy.
- Or patients with Hormonal receptor positive (HR+)/ Human epidermal growth factor receptor 2 negative (HER2-) breast cancer, with treatment failure after a second line of therapy; Estrogen Receptor/ProgesteroneReceptor breast cancer positive patients must have received and progressed on currently recommended therapies in this indication (endocrine therapy, CDK4/6 inhibitors (adjuvant or metastatic)), or have a disease form that the treating physician believes to be inappropriate for recommended therapies in this indication.
- Prior therapy with an anthracycline and a taxane in an adjuvant setting.
- Prior platinum allowed as long as no breast cancer progression occurred on treatment or if given in adjuvant/neoadjuvant setting, at least 12 months elapsed from last dose to study entry.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Adequate bone marrow, kidney and liver function.
- Patients without visceral crisis
Exclusion Criteria:
- Patients with HER2 positive disease.
- Untreated and/or uncontrolled brain metastases.
- Patients in visceral crisis requiring chemotherapy
- Cytopenia, defined with the following thresholds: (i) Neutrophil count < 1500/mm3; Platelet count< 100 000/mm3; Hemoglobin <9g/dL
- Prior malignancy unless curatively treated and disease-free for > 5 years prior to study entry. Prior adequately treated non-melanoma skin cancer, in situ cancer of the cervix, ductal carcinoma in situ (DCIS) or stage I grade 1 endometrial cancer allowed.
- Known HIV (Human Immunodeficiency Virus) infection.
- Pregnant or breast-feeding women.
- Lack of affiliation to a social security benefit plan (as a beneficiary or assignee)
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Niraparib
PARP-inhibitor, Niraparib Dosage : starting 300 mg/day for patients with body weight ≥77kg and platelet counts ≥ 150 000/µl or 200 mg when body weight inferior to 77kg and/or platelet counts ≤ 150 000/µl and > 100 000/µl Pharmaceutical form : 100 mg capsules Posology : single dose daily Route of administration : oral Administration procedures : oral, daily single dose Duration of treatment : 12 cycles of 28 days each
|
Niraparib, once daily
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Objective response rate
Tidsramme: 4 months
|
Complete or partial tumour response according to RECIST 1.1 criteria accounting for objective response rate in solid tumours at 4 cycles., based on the CT-Scan
|
4 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Progression-free survival
Tidsramme: 12 months
|
Time from inclusion to progression or death (all-cause) or last follow-up whichever occurs first
|
12 months
|
Overall survival
Tidsramme: 12 months
|
Time from inclusion to death (all-cause) or last follow-up whichever occurs first
|
12 months
|
Tumoral response
Tidsramme: 12 months
|
Partial Response or Complete Response or Stable Disease, as per to RECIST 1.1 criteria for tumoral response, based on CT-Scan
|
12 months
|
Duration of response
Tidsramme: 12 months
|
Time to treatment failure, defined as time between inclusion and treatment discontinuation (any reason: death, disease progression, toxicity) or last follow-up
|
12 months
|
Adverse event rate
Tidsramme: 72 months
|
Adverse events (clinical and biological) between inclusion and 72 months
|
72 months
|
Quality of Life variation
Tidsramme: 12 months
|
European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life C30 Questionnaire, evaluated every 3 months, from inclusion to 12 month
|
12 months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Forventet)
1. maj 2022
Primær færdiggørelse (Forventet)
1. september 2024
Studieafslutning (Forventet)
1. maj 2030
Datoer for studieregistrering
Først indsendt
28. januar 2022
Først indsendt, der opfyldte QC-kriterier
28. januar 2022
Først opslået (Faktiske)
9. februar 2022
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
8. marts 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
21. februar 2022
Sidst verificeret
1. januar 2022
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- P170929J
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Uafklaret
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Niraparib
-
Tesaro, Inc.Afsluttet
-
Tesaro, Inc.Afsluttet
-
Virginia Commonwealth UniversityGlaxoSmithKline; Puma Biotechnology, Inc.RekrutteringLivmoderhalskræft | Avanceret solid tumorForenede Stater
-
Fudan UniversityRekrutteringBehandlingseffektivitetKina
-
Chongqing University Cancer HospitalRekruttering
-
German Breast GroupGlaxoSmithKline; Stemline Therapeutics, Inc.Ikke rekrutterer endnuBRCA1 mutation | BRCA2 mutation | PALB2-genmutation | Hormonreceptor positiv HER-2 negativ brystkræft | Avanceret eller metastatisk brystkræftTyskland
-
Hunan Cancer HospitalUkendtLivmoderhalskræftKina
-
Abramson Cancer Center at Penn MedicineAktiv, ikke rekrutterendeProstata AdenocarcinomForenede Stater
-
Institut Paoli-CalmettesGlaxoSmithKlineIkke rekrutterer endnu
-
MedSIRIkke rekrutterer endnuLivmoderhalskræft | Oligometastatisk sygdom | Serøs ovarietumor